2008-2012年英格兰与美国老年肺癌患者的诊疗与结局比较
该基于人群的研究链接英格兰与美国癌症登记及行政数据库,比较2008-2012年诊断的66岁及以上NSCLC患者的诊断、治疗和生存模式。结果显示英格兰病理确诊率(63% vs 85%)和积极治疗接受率(46% vs 60%)均低于美国,且英格兰每1000例病理确诊NSCLC患者中多出98例超额死亡,调整分期或分期特异性生存后超额死亡部分减少。
要点
- 英格兰老年NSCLC患者病理确诊率(63%)低于美国(85%),差异为22.2%。
- 英格兰积极治疗接受率(46%)低于美国(60%),差异为14.0%。
- 英格兰每1000例病理确诊NSCLC患者中额外死亡98例,调整分期后降至54例。
核心结论
- 与美国人NSCLC患者相比,英格兰患者较少表现为早期疾病、较少接受治疗且更可能死亡。
研究设计与样本
- 基于人群分析,链接英格兰与美国癌症登记及行政数据库,纳入2008-2012年诊断的66岁及以上NSCLC患者,英格兰86978例,美国84415例。
主要发现
- 英格兰病理确诊率为63%,美国为85%,差异22.2%(99%CI 22.8%-21.7%)。
- 英格兰积极治疗接受率为46%,美国为60%,差异14.0%(99%CI 13.3%-14.7%)。
- 英格兰每1000例病理确诊NSCLC患者中超额死亡98例,调整诊断分期后降至54例,调整分期特异性生存后降至36例。
关键数值与推荐
- 病理确诊率:英格兰63% vs 美国85%,差异22.2%(99%CI 22.8%-21.7%)。
- 积极治疗接受率:英格兰46% vs 美国60%,差异14.0%(99%CI 13.3%-14.7%)。
- 超额死亡:英格兰每1000例病理确诊NSCLC患者98例,调整分期后54例,调整分期特异性生存后36例。
临床怎么用
- 提示英格兰老年NSCLC患者在诊断确认和治疗可及性方面存在差距,需关注资源投入对结局差异的影响。
局限性
- 研究为观察性比较,未明确校正所有混杂因素,且仅纳入66岁及以上患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Although prior research has demonstrated lower lung cancer survival in England than in the United States, more detailed comparisons are needed. We conducted a population-based analysis to compare diagnostic, treatment, and survival patterns. METHODS: Data from cancer registries and administrative databases were linked for older patients with a diagnosis of NSCLC in England and the United States (2008-2012). We compared patient and clinical characteristics, as well as the distribution of age-standardized receipt of treatment by stage. We compared relative survival overall by stage and treatment. Finally, we assessed the degree to which stage distribution and stage-specific survival contributed to survival differences. RESULTS: Among patients age 66 years or older with a diagnosis of NSCLC in England (n = 86,978) and the United States (n = 84,415), the rate of pathological confirmation was 63% in England compared with 85% in the United States (a 22.2% difference [99% confidence interval: 22.8%-21.7%]). The rate of receipt of active treatment was lower in England than in the United States (46% versus 60%, for a difference of 14.0% [99% confidence interval: 13.3%-14.7%]). In England, we identified 98 excess deaths per 1000 patients with pathologically confirmed NSCLC; these additional deaths could be partially mitigated by adjusting stage at diagnosis (reduction to 54 excess deaths) or stage-specific survival (reduction to 36 excess deaths). CONCLUSIONS: Compared with patients with NSCLC in the United States, patients with NSCLC in England are less likely to present with early-stage disease and receive treatment and are more likely to die. Future work should explore whether the intensity of resources directed to diagnostic and therapeutic activity may help mitigate disparities in outcomes.
引用
- Andreano A, Peake MD, Janes SM, et al. The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012. J Thorac Oncol. 2018. PMID: 29727739. doi:10.1016/j.jtho.2018.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。